explore -WSS

explore

author：explore 2025-09-28 00:53:32 - browse：386

Grail spent more than $1 million last quarter lobbying Congress, underscoring the urgency of the company’s bid to secure Medicare coverage for its pricey blood-based cancer screening test that has been on the market for over a year but is not widely used.

A recently posted lobbying report indicates that, during the fourth quarter of last year, the biotech spent $1.07 million on “issues related to oncology and multi-cancer early detection,” including House and Senate bills that would allow Medicare to cover multi-cancer screening tests. That figure has been rising; during the fourth quarter of 2021, the company spent $470,000 on lobbying. That’s far more than cancer and genetic testing biotechs such as Guardant Health, Myriad Genetics, and Tempus, which spent anywhere from $90,000 to nearly $300,000 on lobbying last quarter.

The growing investment in lobbying elected officials comes at a time when Grail is looking to make its test, Galleri, available to a broader swath of the population. The test, launched in 2021, can detect early signs of more than 50 cancers among people who don’t have symptoms. That’s because cancer cells release bits of DNA into the bloodstream, and Galleri spots telltale modifications to this DNA.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： What to make of Biden’s latest efforts on cancer research

explore

WSS

STAT series 'Denied by AI' wins major journalism prizes

Raw milk easy to obtain despite bird flu warning, FDA interstate ban

Adam's Biotech Scorecard: PDS Biotech's survival benefit is overstated

Oak Street deal isn't the answer to health care's woes

Obesity drug from Roche shows promise in early study

New weight loss drugs vying to be the next Wegovy or Mounjaro

knowledge

explore

Wikipedia

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

FDA proposes changes to key medical devices approval pathway

23andMe had bad news about my health. I wish a person had delivered it

Obesity drug from Roche shows promise in early study

What does generative AI mean for health care? We asked experts

WATCH: Why do bright lights make us see spots?

DIEP, the 'gold standard' of breast reconstruction, is under threat

Food makers to regulators: Ultra

Medical leaders decry Supreme Court decision on affirmative action

PEPFAR is under serious threat — and so is global health

explore

Hospitals consider fixing cancer drug shortages on their own

Food makers tried to stack nutrition panel with preferred experts

What a koala virus tells us about the human genome

Readout Newsletter: Raw milk, Wegovy tests, Eisai and Biogen

FDA proposes changes to key medical devices approval pathway

Will the IRA bring competition to the biologics market?

focus

explore

entertainment

leisure time